Abstract library

13 results for "Jeller".
#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas
Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#272 Plasma Chromogranin A in Patients with MEN I and Pancreatic Endocrine Tumors
Introduction: Circulating chromogranin A(CgA) is considered a useful marker for gastroenteropancreatic endocrine tumors. Data on its pattern in MEN-1 patients with non-functioning pancreatic tumors(NFPT) are scant.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Roberta E Rossi
#534 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors
Introduction: Despite encouraging results of streptozocin combinations in patients with metastatic endocrine pancreatic tumors, this treatment modality consists of a five-day cycle and can cause renal insufficiency. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Daniela Müller
Authors: Müller D, Rinke A, Gress T, ...
#711 Risk of Recurrence in Patients with Neuroendocrine Tumors After R0-Resection
Introduction: Operative treatment with curative intention is still the corner stone of all recommendations. Risk of recurrence and time frame for follow-up is not well-defined.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Anja Rinke
Keywords: NEN, recurrence, grade, stage
#754 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors
Introduction: Streptozocin-based chemotherapies are widely used in pancreatic NEN. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Daniela Mueller
Authors: Mueller D, Krug S, Majumder M, Gress T, ...
Keywords: NEN, DTIC, MGMT
#805 Clinically Detected Gastroenteropancreatic Neuroendocrine Tumors are on the Rise: Epidemiological Changes in Germany
Introduction: -
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. med. Jan Eick
Keywords: GEP-NET, Germany
#825 Brain Metastases in Neuroendocrine Tumor Patients: Frequency and Outcome
Introduction: Brain metastases are rarely reported in patients with neuroendocrine carcinoma (NEC) of non-lung origin and neuroendocrine tumors (NETs) of the gastroenteropancreatic or bronchopulmonary system. Symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Anja Rinke
Authors: Rinke A, Müller D, König A, Arnold R, ...
#841 Quality of Life in Neuroendocrine Tumor Patients Compared to the General Population
Introduction: Literature on NET patients' quality of life (QOL) is scarce.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: PhD Eva M Gamper
Keywords: quality of life